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(1) have inadvertently selected a subpopulation of DES patients
more prone to restenosis. Therefore, it seems that these patients
exhibited resistance to the antiproliferative and immunosuppres-
sive drugs released by DES. Consequently, it is plausible that this
subpopulation expresses various biological factors that may also
reduce the ability to generate collateral vessels. Hence, it may be
premature to consider DES as the leading factor contributing to
reduced collateral formation, until a study using widely patent
DES and BMS confirms this.
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Reply
We thank, respectively, Drs. di Mario and Dimopoulos and Drs.
Parent and Rinfret for their comments on our work (1). In fact, it
was conceived on the basis of experimental and clinical evidence
suggesting that local rapamycin or paclitaxel could have an adverse
effect on circulating monocytes (2), respectively, that coronary
endothelial function in humans is compromised up- as well as
downstream of the stent eluting such drugs (3,4). Thus, the
“broader context” requested by Parent and Rinfret actually incited
the study. It is, indeed, the case that the restenosis severity in the
stented segment was pronounced, and that the question may be
raised whether our study population is representative for all
patients receiving drug-eluting stents (DES). In the context of a
rather prominent in-stent restenosis, the reasoning by Parent and
Rinfret can even be followed to the point where they hypothesize
“resistance to the antiproliferative and immunosuppressive drugs”
in the DES group. However, to link the proposed opposition to
antiproliferation with impaired collateral growth is, even semanti-
cally, an oxymoron. This is because all the evidence of the past 40
years has very convincingly conveyed 1 message: collateral growth
is intimately tied to inflammatory (i.e., proliferative) processes (5).
It is correct that after stent implantation, there is no stimulus for
collateral development. However, our study has not focused on
stimuli, but on potential anti-stimuli of collateral growth. Further-
more, rapamycin and paclitaxel have been shown by independent
groups to elicit an adverse effect on endothelial function both up-
and downstream of the implantation site. Drs. di Mario and
Dimopoulos also claim that alternative ways of data analysis would
have probably uncovered their frail character. First, to apply the
proposed nonparametric statistical analysis provides 38 higher
collateral flow index ranks in the bare-metal stent (BMS) than in
the DES group, and 21 lower ranks (p  0.0020). Second, it was
maybe not pointed out clearly enough that ours was a study with
a matched design for stenosis severity at the time of follow-up. In
this context, Table 3 of our article has already provided the
fractional flow reserve values (0.828  0.184 vs. 0.838  0.177)
asked for by di Mario and Dimopoulos, thus documenting that the
paired stenotic lesions were well comparable hemodynamically.
Third, Table 3 of our article has displayed even more information
(i.e., electrocardiogram [ECG] data against the argument that the
CFI difference between the groups “is unlikely to be clinically
relevant”: signs of ischemia during coronary balloon occlusion on
intracoronary ECG were present in 33 of 60 patients in the BMS
group, but in 50 of 60 patients of the DES group). The magnitude
of ECG ST-segment elevation during a temporary occlusion has
been and is employed as a surrogate marker for infarct size in case
of a permanent occlusion for decades. As di Mario and Dimopou-
los certainly know, infarct size is gradually and not binarily
influenced by the product of coronary occlusion time, myocardial
area at risk, oxygen consumption at and during the time of
occlusion, and the inverse of collateral supply.
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